IC
Ikarian Capital Portfolio holdings
AUM
$302M
This Quarter Return
+0.62%
1 Year Return
+65.21%
3 Year Return
+441.33%
5 Year Return
+548.26%
10 Year Return
–
AUM
$437M
AUM Growth
+$437M
(-22%)
Cap. Flow
-$126M
Cap. Flow
% of AUM
-28.81%
Top 10 Holdings %
Top 10 Hldgs %
31.44%
Holding
211
New
18
Increased
20
Reduced
105
Closed
27
Top Buys
| 1 |
BCYC
Bicycle Therapeutics
BCYC
|
$21.9M |
| 2 |
Apellis Pharmaceuticals
APLS
|
$11.5M |
| 3 |
INBX
Inhibrx, Inc. Common Stock
INBX
|
$9.39M |
| 4 |
Immatics
IMTX
|
$8.55M |
| 5 |
Zentalis Pharmaceuticals
ZNTL
|
$6.15M |
Top Sells
| 1 |
WHWK
Whitehawk Therapeutics, Inc. Common Stock
WHWK
|
$48.9M |
| 2 |
Biogen
BIIB
|
$26.5M |
| 3 |
Alector
ALEC
|
$14.1M |
| 4 |
CRISPR Therapeutics
CRSP
|
$10.3M |
| 5 |
Annovis Bio
ANVS
|
$8.86M |
Sector Composition
| 1 | Healthcare | 97.59% |
| 2 | Consumer Staples | 0.77% |
| 3 | Technology | 0.56% |
| 4 | Financials | 0.17% |
| 5 | Real Estate | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
BCYC
1
Bicycle Therapeutics
BCYC
$511M
| $21.9M | 1.54% | +526,500 | New | +$21.9M |
|
2
Gossamer Bio
GOSS
$562M
| $17M | 1.2% | 1,351,933 +303,550 | +29% | +$3.82M |
|
3
Celldex Therapeutics
CLDX
$1.47B
| $14.6M | 1.03% | 270,431 -95,113 | -26% | -$5.13M |
|
4
Cabaletta Bio
CABA
$133M
| $14.4M | 1.02% | 1,187,898 +240,770 | +25% | +$2.93M |
|
5
X4 Pharmaceuticals
XFOR
$84.2M
| $13.4M | 0.95% | 2,539,917 -179,373 | -7% | -$949K |
|
|
SRRA
6
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $12.6M | 0.89% | 573,380 +28,378 | +5% | +$622K |
|
|
7
Immatics
IMTX
$619M
| $11.5M | 0.81% | 883,046 +657,908 | +292% | +$8.55M |
|
|
8
Apellis Pharmaceuticals
APLS
$3.48B
| $11.5M | 0.81% | +347,545 | New | +$11.5M |
|
|
TCON
9
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
| $10.4M | 0.73% | 2,691,110 -25,730 | -0.9% | -$99.6K |
|
10
Milestone Pharmaceuticals
MIST
$156M
| $9.99M | 0.7% | 1,750,043 -230,357 | -12% | -$1.32M |
|
|
INBX
11
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $9.65M | 0.68% | 289,850 +281,774 | +3,489% | +$9.39M |
|
|
12
Biogen
BIIB
$19.4B
| $9.12M | 0.64% | 32,243 -93,719 | -74% | -$26.5M |
|
|
ITCI
13
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $7.89M | 0.56% | 211,670 -19,219 | -8% | -$716K |
|
14
Vaxcyte
PCVX
$4B
| $7.49M | 0.53% | 295,111 -152,999 | -34% | -$3.88M |
|
|
CMPS
15
Compass Pathways
CMPS
$424M
| $6.85M | 0.48% | 229,202 +144,139 | +169% | +$4.31M |
|
|
16
Zentalis Pharmaceuticals
ZNTL
$122M
| $6.15M | 0.43% | +92,344 | New | +$6.15M |
|
|
AYLA
17
DELISTED
Ayala Pharmaceuticals, Inc. Common Stock
AYLA
| $6.11M | 0.43% | +538,939 | New | +$6.11M |
|
18
scPharmaceuticals
SCPH
$295M
| $5.99M | 0.42% | 901,362 -193,662 | -18% | -$1.29M |
|
19
BioAtla
BCAB
$26.7M
| $5.78M | 0.41% | 196,400 +126,240 | +180% | +$3.72M |
|
20
Xenon Pharmaceuticals
XENE
$2.98B
| $5.77M | 0.41% | 377,438 -263,168 | -41% | -$4.02M |
|
|
ODT
21
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
| $5.36M | 0.38% | 1,840,631 -145,781 | -7% | -$424K |
|
|
ATYR
22
aTyr Pharma
ATYR
$527M
| $5.11M | 0.36% | 562,246 +262,246 | +87% | +$2.38M |
|
|
CLVS
23
DELISTED
Clovis Oncology, Inc.
CLVS
| $4.96M | 0.35% | 1,112,669 -16,804 | -1% | -$75K |
|
|
CMRX
24
DELISTED
Chimerix, Inc.
CMRX
| $4.96M | 0.35% | 801,308 -774,608 | -49% | -$4.79M |
|
25
Wave Life Sciences
WVE
$1.53B
| $4.87M | 0.34% | +993,481 | New | +$4.87M |
|